The U.S. Food and Drug Administration has approved an updated label for Unloxcyt (cosibelimab-ipdl) for the treatment of ...

Lytgobi (futibatinib) marks the first medicine launched by Taiho Oncology Europe in the UK (2) For United Kingdom (UK) Trade and Medical Media Only ...

Cancer is a leading cause of death worldwide, and among all cancers, colorectal cancer ranks second in mortality, responsible ...

Sacituzumab tirumotecan demonstrated a 31% objective response rate and 71% disease control rate in advanced urothelial ...

Grab your loupes and your favorite coffee mug — it is time to head into the world of metastatic spine disease.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic or locally advanced somatostatin ...

In the first part of this interview, Gupta discussed the basics of GIST, and now he breaks down his advice for newly ...

Pemigatinib was well-tolerated among patients with CCA regardless of presence of CUP, but HCRU costs were higher with CUP vs without CUP.

CURE recently sat down with Dr. Ajay Gupta of the Roswell Park Comprehensive Cancer Center in Buffalo, New York, to discuss what patients should do if they have recently received a diagnosis of ...

A cancer diagnosis changes life in several ways, but when cancer becomes metastatic, meaning the disease spreads beyond the ...

This satellite symposium at the European Society for Medical Oncology (ESMO) Congress 2025, chaired by Rana McKay, Professor ...

PPGLs show marked skeletal tropism, with 75.7% of patients developing bone metastases, primarily in the spine, after surgical resection.